DarshanTalks Podcast
Welcome to DarshanTalks!
We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there!
Powered By The Kulkarni Law Firm - Helping regulators see your business the way you do.
We focus on life science issues involving medical affairs, marketing and advertising, and clinical research so that you can learn about the industry, enhance your business and grow your career.
DarshanTalks Podcast
Payer Presentations Can Trigger Enforcement
The boundary between scientific exchange and marketing in payer presentations is increasingly blurred, creating significant compliance and enforcement risks. While payers demand real-world evidence, comparative studies, and economic models beyond FDA-approved labeling, manufacturers must ensure all shared information is truthful, non-misleading, properly contextualized, and backed by competent and reliable scientific evidence.
Key pitfalls include:
- Cherry-picking data without balanced limitations.
- Economic models presented without caveats or assumptions.
- Future indications framed as imminent rather than investigational.
Crossing into promotion can trigger FDA, FTC, OIG, DOJ, and plaintiff scrutiny, with false claims liability a real risk. To mitigate exposure, companies should:
- Use clear disclaimers and transparent disclosures.
- Involve compliance early in deck preparation.
- Document rationale, recipients, and underlying assumptions.
- Maintain audit trails through tools like Ceres Tracking.
The DOJ’s healthcare fraud task force has prioritized this area, making compliance essential not only to avoid regulatory letters but also subpoenas, litigation, and treble damages. Proper safeguards—including playbooks, legal review, and compliance monitoring—protect companies from costly enforcement actions.
Bottom line: Scientific exchange with payers is permitted and necessary, but once it drifts into marketing, companies face severe legal and financial consequences.
